anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
When thinking about major health concerns in the U.S. and around the world, eye care ranks lower compared to cardiovascular disease, cancer, and diabetes. However, people do not think about the direct connection between diabetes and eye health. Untreated diabetes can lead to visual impairments such as blindness or difficulty seeing. Studies have found that eye health associated with nutrition, occupational exposure, diabetes, high blood pressure, and heart disease are some of the known risk factors. This study aimed to identify the potential risk factors that are associated with visual impairment (VI). The data used for this analysis were obtained from the Centers for Disease Control and Prevention (CDC) - Behavioral Risk Factor Surveillance System (BRFSS) from 2018 to 2021. We found important characteristics, such as the U.S. region, general health perception, employment status, income status, age, and health insurance source, that are associated with VI. Our study confirmed that the common demographical factors including age, race/ethnicity, the U.S. region, and gender are associated with VI. The study also highlights associations with additional risk factors such as health insurance source, general health perceptions, employment status, and income status. Using this information, we can reach out to communities with large numbers of individuals experiencing vision challenges and help educate them on prevention and treatment protocols, thereby effectively addressing VI and blindness challenges within our communities, neighborhoods, and finally, the broader society.
Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.
Systems and methods for modifying a user's environment based on physiological data collected from a wearable device is described. For example, a physiological modification system for modifying the environment of the user may include a data receiving module, a physiological event module, an instruction module, and an efficacy module. The data receiving module receives current physiological data from the user. The physiological event module identifies a physiological event based on the current physiological data. The instruction module generates an instruction based on the physiological event. The instruction includes at least one action to be executed by an environmental device. The efficacy module calculates an efficacy level of the at least one action based on post-action physiological data.
All participants will receive the intervention (eToke+TPsy). The intervention consists of eToke (a brief computerized intervention that uses motivational enhancement therapy to improve readiness to decrease cannabis use and increase motivation to engage in substance use treatment) AND 6-8 interactive text messages regarding cannabis use reduction over 4 weeks . Text messages will contain written content, and queries, as well as links to publicly available websites and YouTube videos.
Patients in this group have had a SPECT MPI examination that is positive for ischemia in two myocardial segments and have been referred for invasive coronary angiography (ICA) as part of their routine standard-of-care. Subjects will undergo \[68Ga\]Galmydar PET/CT prior to any intervention. Participants will receive one \[68Ga\]Galmydar intravenous administration, 2 mCi during rest.
The invention relates to a preparation method and an application of a plant extract and particularly relates to a preparation method of thyrsiferol and application of thyrsiferol in preparing anti-leukemia medicines. The preparation method comprises the following steps: (1) taking Laurencia thyrsifera Hook. coarse powder, and carrying out continuous counter-current ultrasonic extraction by a 90% ethanol solution to obtain an extracting solution; (2) concentrating the extracting solution, and carrying out chromatography by alumina column; (3) carrying out preparative liquid-phase chromatograph; (4) recrystallizing by acetone to obtain a high-purity thyrsiferol crystal product. The preparation method provided by the invention is simple and convenient in process operation, high in yield, small in pollution and suitable for production of high-purity thyrsiferol. The thyrsiferol has an anti-tumor effect. Pharmacological experiments show that the thyrsiferol has a good effect in anti-tumor aspect, is especially better in effect of treating human lymphocytic leukemia (P388), and can be used for preparing the anti-leukemia medicines.
A non-aqueous, anti-microbial, anti-fungal, low pH, lubricating and moisturizing composition adapted for topical or intra-vaginal use during sexual intercourse, the composition consisting essentially of approximately 55-70 vol. % shea butter, approximately 25-40 vol. % coconut oil and approximately 1-5 vol. % grapeseed oil. The composition may further contain no more than approximately 2 vol. % of a scenting component. The composition possesses a low pH to counter the pH elevating effects of semen, soap, menopause and menstruation.
The present invention relates to a blood coagulation factor ? derivative, a blood coagulation factor ?a derivative, Fac? and Fac?a conjugates each prepared by linking a polymer capable of extending the blood half-life to the derivative, Fac? and ?a complexes each prepared by linking a carrier to the conjugate, genes encoding the Fac? and Fac?a derivatives, expression vectors comprising the genes, transformants introduced with the expression vectors, a method for preparing the Fac? and Fac?a derivatives using the transformants, a method for preparing the Fac?a conjugate and complex, a Fac?a complex prepared by the method, a pharmaceutical composition for the prevention or treatment of hemophilia comprising the derivative, conjugate, or complex as an active ingredient, and a pharmaceutical composition for blood coagulation comprising the derivative, conjugate, or complex as an active ingredient. Further, the present invention relates to a method for preventing or treating hemophilia or for promoting blood coagulation, comprising administering to a subject a therapeutically effective amount of the composition. The Fac? or Fac?a derivative of the present invention is able to bind with a carrier capable of improving the blood half-life while maintaining the activity of Fac? or Fac?a, and they can be widely used in the development of effective prophylactic or therapeutic agent for hemophilia.
Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most prevalent chronic liver diseases in Brazil. It has a significantly increasing incidence today and is considered an important global health problem. It affects approximately 20 to 30% of the adult population and increases according to the severity of the risk factors. The diagnosis of this disease usually occurs in 10 to 20% of the non-obese individuals, 50% in the overweight and 80 to 90% in the obese, being twice as present in individuals with Metabolic Syndrome. Pharmacological treatment options for NAFLD are still limited and Silybum marianum, one of the most sought-after herbal remedies in patients with liver disease, is commonly used by patients because of the claim of the hepatoprotective effect of silymarin. Studies have demonstrated the therapeutic potential of silymarin in patients with NAFLD, but clinical trials with more judicious methodological designs is still needed to prove these effects. Thus, this project aims to evaluate the efficacy of silymarin in adult patients with NAFLD seen at the Clinic of Nutrition and Hepatology of Edgard Santos Hospital. A randomized, double-blind, controlled clinical trial lasting 12 weeks will be performed.
PURPOSE: To evaluate the effects of sodium hyaluronate drops on dry eye parameters and corneal epithelial thickness following cataract surgery.
METHODS: The study included 84 patients who underwent uncomplicated phacoemulsification. In Group A, 0.15% sodium hyaluronate drops were added to the postoperative antibiotic/anti-inflammatory treatment. In Group B, only antibiotic/anti-inflammatory treatment was applied. Preoperatively and at 1 week and 1 month postoperatively, all the patients were evaluated in respect of tear break-up time (TBUT), the Schirmer test under anesthesia, the corneal fluorescein staining (CFS) score, mean central corneal thickness (CCT) and mean central corneal epithelial thickness (CCET), and the two groups were compared.
RESULTS: A statistically significant difference was determined between the two groups at postoperative 1 month in respect of TBUT, Schirmer test, CFS score, and CCET (p < 0.01). In Group A, a statistically significant increase was determined in the TBUT and Schirmer values at 1 month postoperatively (p < 0.01, p = 0.01, respectively) and in Group B, these values were decreased compared to preoperatively (p < 0.01). The CCET was determined to be significantly thinner in Group B 1 month postoperatively (p < 0.01). A significant increase in CCT was observed in both groups at postoperative 1 week (p < 0.01) and preoperative values were reached at 1 month postoperatively.
CONCLUSION: In the patient group using sodium hyaluronate, significant differences were determined in all dry eye parameters and CCET. The use of hyaluronate sodium drops after cataract surgery was seen to improve dry eye parameters and contribute to a healthy ocular surface by ensuring continuity of the corneal epithelium.
PURPOSE: Provided is simple and exact means for judging whether or not a component to be used for a head skin or head hair reaches a point of application and a method for evaluating sebum migration of a specimen. CONSTITUTION: The method evaluates sebum migration of a specimen with an index of migration degree of the specimen to an artificial sebum by making one surface of a thin film(12) similar to a skin surface come into contact with the specimen, with the other side surface thereof in contact with an artificial sebum. In this method one side of the thin film has an open system. The artificial sebum is a fluid state. The thin film is a single layer silicone film a surface of which is subjected to keratin treatment. The specimen is made to come into contact with the keratin treatment side of the film. An evaluation kit for evaluating migration of sebum comprises a sealing portion of an artificial sebum, provided in an opening portion thereof with fixing means capable of fixing and covering detachably the thin film; a thin film similar to a skin surface layer to be fixed on and cover the opening portion of the sealing portion; and an artificial sebum to be sealed in the sealing portion. The head skin and head hair composition contains isostearyl alcohol as a skin migration acceleration component.
This is a randomized, double-blind clinical trial, parallel, placebo-controlled trial. Breast cancer women treated surgically and with indication for adjuvant chemotherapy, aged between 18 and 75 years will be included. Patients will be randomized to receive 20mg of melatonin or placebo at bedtime. Treatment will initiate seven days before the start of chemotherapy to three days after the first cycle, totaling ten days. The sleep-wake rhythm will be assessed by actigraphy, which use will precede three days to start treatment. We will also evaluate the sleep-wake cycle by sleep diary. Other parameters will be measured as depressive symptoms, pain threshold pressure, effect on platelets and white series, the pain response to conditioned stimuli and quality of life. Serum markers of neuroplasticity will be measured as the Derivate Nerve Factor Brain BDNF and S100 β. The icronucleus effect will quantified by cell material from the oral mucosa. We expect that the use of melatonin, as a competitor to chemotherapy and synchronizer, improves tolerance to adjuvant treatment of breast cancer chemotherapy adverse effects.
Participants will use Voltaren Gel 1 percent (%) (in the US) or Voltaren Gel 1.16% or Voltaren Gel 2.32% (in the EU) topically, applied daily as per label and leaflet instructions for up to 21 days. Participants will be instructed to wear Actigraph device on the wrist as per label, leaflet or site-specific instructions post training throughout the day for up to 21 days.
1. Top pole support for aerial electric power lines, in particular with suspended wires in which said aerial electric power lines comprise at least three wires (14) and said top pole support (10; 20; 40) comprise corresponding insulating means (13), in particular suspended insulators, to hold said wires (14) characterized in that said top pole support (20; 40) traces a continuous curve substantially passing by the point in which the insulating means (13) are. 2. Top pole support for aerial electric power lines, in particular with suspended wires, according to claim 1, characterized in that said top pole (20) traces a continuous open curve. 3. Top pole support for aerial electric power lines, in particular with suspended wires, according to claim 1, characterized in that said top pole support (20; 40) is fastened through a crate (25) to the pole (11). 4. Top pole support for aerial electric power lines, in particular with suspended wires according to claim 2, characterized in that said continuous open curve comprises a bend (22b), a lower arm (22c) and an upper arm (22a). 5. Top pole support for aerial electric power lines, in particular with suspended wires, according to claim 4, characterized in that the insulating means (13 in particular suspended insulators, are connected to the extremity of the lower arm (22c), of the upper arm (22a) and on the external part of the bend (22b). 6. Top pole support for aerial electric power lines, in particular with suspended wires, according to at least one of the preceding claims, characterized in that said top pole support (20) is carried out through a tubular element. 7. Top pole support for aerial electric power lines, in particular with suspended wires, according to at least claim 2, characterized in that said top pole support (40) traces an open continue curve that does not lie in only one plane. 8. Top pole support for aerial electric power lines, in particular with suspended wires, according to at least claim 2, characterized in that said top pole support (40) is spiral shaped with a bent part (42a) and two arms (42b, 42c) to the extremities substantially symmetrical in the plane of the spiral.
Patients receive acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks). These patients also received corticosteroid for 4 weeks, methylprednisolone 80mg ivdrip. for 3 days, 60mg ivdrip. for 3 days, 40mg ivdrip. for 3 days, 30mg po. for 7 days, 20mg po. for 7 days, 10mg po. for 5 days and maintain.
Participants in this group will serve as controls prior to participating in power training in 1 of the above treatment groups. The control period will last as long as the exercise period, or 3 months. Controls will participate in the same testing time points as the exercisers (baseline, midpoint, and post-intervention).
Components of the ICU RC telehealth visit will be structured parallel to what is done during a typical in-person clinic visit. The telehealth intervention consists of 5 chronological components conducted during two 1.5 hour telehealth clinic visits (the same time required for an in-person visit). Upon completion of the pre-intervention baseline assessment, the study coordinator will contact patients randomized to the intervention arm to schedule the first telehealth visit. Study visits will occur at 3 weeks and 3 months following hospital discharge.
Polypharmacy exacerbates lower urinary tract symptoms (LUTS). Japan exhibits a higher prevalence of concomitant medication use in drug therapy than other countries. Previous age- and sex-specific reports exist; however, none include patients of all ages. Therefore, this retrospective study determined the impact of polypharmacy and its associated risk factors on LUTS exacerbation in outpatients with urological conditions. We included patients receiving medication who visited the Department of Urology at the Gifu Municipal Hospital (Gifu, Japan) between January, 2018 and December, 2018. The association between LUTS and polypharmacy and the risk factors for LUTS exacerbation were investigated. Patients were categorized into two groups according to their polypharmacy status. We performed propensity score matching and compared the International Prostate Symptom Score (IPSS) between the groups using the unpaired t-test. Multiple logistic regression analysis was performed to examine the risk factors, including "polypharmacy" and "taking multiple anticholinergic medications" for LUTS exacerbation. When comparing the IPSS between the groups, the polypharmacy group was found to have significantly higher scores than the non-polypharmacy group in six items, including "total score" and "storage score." Multiple logistic regression analysis results showed high significance in three items, including "polypharmacy" (odds ratio (OR) = 1.67, 95% confidence interval (CI): 1.03-2.71) and "taking multiple anticholinergic medications" (OR = 8.68, 95% CI: 1.05-71.7). In conclusion, this study revealed that "polypharmacy" and "taking multiple anticholinergic medications" were risk factors for LUTS. Particularly, "polypharmacy" is associated with storage symptom exacerbation. Therefore, eliminating "polypharmacy" and "taking multiple anticholinergic medications" is expected to improve LUTS.
<P>PROBLEM TO BE SOLVED: To provide a composition and a method for stimulation or inhibition of angiogenesis and/or cardiovascular plasty in mammals including human beings.  <P>SOLUTION: A pharmaceutical composition based on polypeptides or antagonists thereof identified in terms of one or a plurality of these usages is provided. Diseases which are diagnosed, prevented or treated with the composition comprises injury such as wound, various cancers, and vascular diseases including atherosclerosis and cardiac hypertrophy. In addition, this invention provides novel polypeptides and a nucleic acid molecule encoding these polypeptides. Moreover, a vector and host cell including these nucleic acid sequences, a chimeric polypeptide molecule including these polypeptides fused with a different kind of polypeptide, an antibody binding to these polypeptides, and a method for producing these polypeptides are provided.  <P>COPYRIGHT: (C)2004,JPO
HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
AIMS: A high-intensity care (HIC) strategy with rapid guideline-directed medical therapy (GDMT) up-titration and close follow-up visits improved outcomes, compared to usual care (UC), in patients recently hospitalized for acute heart failure (AHF). Hypotension is a major limitation to GDMT implementation. We aimed to assess the impact of baseline systolic blood pressure (SBP) on the effects of HIC versus UC and the role of early SBP changes in STRONG-HF.
METHODS AND RESULTS: A total of 1075 patients hospitalized for AHF with SBP ≥100 mmHg were included in STRONG-HF. For the purpose of this post-hoc analysis, patients were stratified by tertiles of baseline SBP (<118, 118-128, and ≥129 mmHg) and, in the HIC arm, by tertiles of changes in SBP from the values measured before discharge to those measured at 1 week after discharge (≥2 mmHg increase, ≤7 mmHg decrease to <2 mmHg increase, and ≥8 mmHg decrease). The primary endpoint was 180-day heart failure rehospitalization or death. The effect of HIC versus UC on the primary endpoint was independent of baseline SBP evaluated as tertiles (pinteraction = 0.77) or as a continuous variable (pinteraction = 0.91). In the HIC arm, patients with increased, stable and decreased SBP at 1 week reached 83.5%, 76.2% and 75.3% of target doses of GDMT at day 90. The risk of the primary endpoint was not significantly different between patients with different SBP changes at 1 week (adjusted p = 0.46).
CONCLUSIONS: In STRONG-HF, the benefits of HIC versus UC were independent of baseline SBP. Rapid GDMT up-titration was performed also in patients with an early SBP drop, resulting in similar 180-day outcome as compared to patients with stable or increased SBP.
543,458. Cleansing preparations. McKIM, O. E. May 7, 1940, No. 8229. [Class 91] A liquid preparation for cleansing removable dentures comprises a saturated aqueous solution of citric acid together with isopropyl alcohol and distilled water. An example is given of a preparation containing these ingredients, as well as oil of spearmint and saccharin to provide a palatable flavour and oil of neutroleum to give a pleasing aroma.
Kidney fibrosis is one of the complications of chronic kidney disease (CKD (and contributes to end-stage renal disease which requires dialysis and kidney transplantation. Several signaling pathways such as renin-angiotensin system (RAS), microRNAs (miRNAs) and transforming growth factor-β1 (TGF-β1)/Smad have a prominent role in pathophysiology and progression of renal fibrosis. Activation of classical RAS, the elevation of angiotensin II (Ang II) production and overexpression of AT1R, develop renal fibrosis via TGF-β/Smad pathway. While the non-classical RAS arm, Ang 1-7/AT2R, MasR reveals an anti-fibrotic effect via antagonizing Ang II. This review focused on studies illustrating the interaction of RAS with sexual female hormone estradiol and miRNAs in the progression of renal fibrosis with more emphasis on the TGF-β signaling pathway. MiRNAs, especially miRNA-21 and miRNA-29 showed regulatory effects in renal fibrosis. Also, 17β-estradiol (E2) is a renoprotective hormone that improved renal fibrosis. Beneficial effects of ACE inhibitors and ARBs are reported in the prevention of renal fibrosis in patients. Future studies are also merited to delineate the new therapy strategies such as miRNAs targeting, combination therapy of E2 or HRT, ACEis, and ARBs with miRNAs mimics and antagomirs in CKD to provide a new therapeutic approach for kidney patients.
Rituximab is a human-mouse chimeric monoclonal antibody that targets the B-cell CD20. It is an indispensible drug for the treatment of B-cell lymphoproliferative syndrome which induced immunosuppression. So, the infectious complications increase. Reactivation of hepatitis B virus is one such complication that can lead in asymptomatic hepatitis to death. Prevention of hepatitis B reactivation is recommended like using nucleoside analog for patients with chronic hepatitis B or occult hepatitis and vaccination against virus for seronegative patients. The published data about efficacy of hepatitis b vaccination in onco-haematology are rare. therefore, we carried out a prospective study to assess efficacy of hepatitis B vaccination in patients with lymphoproliferative disorder.